Discover the Expertise of Dr. Jelle Barentsz

Dr. Jelle Barentsz is a pioneering radiologist dedicated to advancing prostate cancer diagnosis through innovative MRI techniques.

Non-Radiology Images

My hobby is photography. If you would like to view my work, including flowers, landscapes, birds, mammals, sea-life, and insects, please visit my non-radiology site.

https://www.jellebarentsz.com

https://barentsz-nature-photography.com

Nederlandse Biografie /
Dutch Biography

Hier kunt u lezen wie ik ben, wat ik heb meegemaakt en wat mijn professionele passies zijn.

Professional Biography (English)

With a remarkable career kicking off in 1980 as an MD, Dr. Barentsz went on to achieve his research PhD in 1990. Since 1998, he has been a pioneering radiology professor and is currently based at the Division of Medical Imaging at the Andros Clinics. His innovative research has made a lasting impact on the field, particularly with the introduction of

PI-RADS, which is now widely recognized as the premier standard for prostate MRI globally. The influential '4M' paper and his other published works have played a significant role in shaping European and Dutch prostate cancer recommendations, advocating for prostate MRI before undergoing biopsy.

Discover Dr. Barentsz's groundbreaking research that has reignited interest in ferumoxtran macrophage-(m)MRI. This cutting-edge technology uses dextran-coated iron nanoparticles as an MRI contrast agent to spot 2mm lymph node micro-metastases. Currently, this innovative method is undergoing a marketing approval trial in Germany, Switzerland, and The Netherlands. It has the potential to transform the field of medical imaging. Learn more about m-MRI.

Papers and Courses and Presentations

Discover the impactful contributions of Dr. Barentsz in the field of prostate cancer imaging, encompassing research papers, educational courses, engaging presentations, and expert insights.

Accuracy of Nano-MRI

Combidex has asensitivity of 88%and aspecificity of 93%in detecting small lymph node metastases

Learn More

Astellas/MAGNIFY trial

Assessing the value of novel molecular imaging techniques: multiparametric MRI

Learn More

Biography

Dr. Jelle Barentsz is a pioneering radiologist dedicated to advancing prostate cancer diagnosis .

Learn More

Dr. Barentsz' research focuses on the following aims:

1. Introduce PSA testing combined with prostate MRI for early detection and screening of prostate cancer. Use artificial intelligence to ensure high-quality MRI scans and to support accurate image interpretation.

2. Provide international, interactive, hands-on online training to help radiologists become experts in prostate MRI. Establish strong quality control through accreditation and certification, and build an international network of excellence in prostate MRI.

3. Achieve global regulatory approval of ferumoxtran as an MRI contrast agent, and implement macrophage-targeted MRI to detect and selectively treat tiny (2 mm) lymph node metastases, as well as applications in multiple sclerosis and atherosclerosis.

4. Establish an International Prostate MRI Reference Centre for excellence in diagnosis and treatment.

5. Develop a biological cell therapy that selectively destroys cancer cells.

Dedication, Innovation, and Impact in Prostate Cancer Care

He is known for his determination and sometimes stubborn nature in making decisions, but he is also open to good ideas. For example, when he suggested using MRI to detect clinically significant prostate cancer, urologists initially opposed the idea. However, he persevered and has now been honored with the 2020 EAU Innovators in Urology Award and Platinum Award in 2026 by European urologists.

He also holds the position of Imaging Editor on the Executive Editorial Board of European Urology, where he works to promote imaging tools that benefit patients. In his pursuit of these goals, he can sometimes become impatient due to his strong commitment and passion. He occasionally forgets that changes in medical care may take time. He is frequently sought after as a member of the Prostate Cancer Patient Society's Advisory Board and willingly assists many patients, even outside normal working hours, providing them with imaging support.

In addition, he actively contributes to research in the field of prostate cancer imaging and therapy. His expertise and dedication have made him a respected figure in the medical community. He is known for his willingness to go above and beyond helping patients, even providing support outside of regular working hours.

He has authored over 360 papers, with seven published within the past two years. His h-factor is 110 with more than 50,000 citations (Google Scholar). Consequently, he has inspired numerous young researchers to produce exceptional articles.

Furthermore, he frequently presents his work at national and international conferences, contributing to the dissemination of knowledge in the field. He actively participates in collaborations with other institutions and clinicians, aiming to advance the effectiveness and accessibility of prostate cancer diagnosis and treatment.

Moreover, his dedication to education is evident in his role as a mentor and supervisor for medical students, residents, and fellows interested in prostate cancer imaging and therapy.

Patients and colleagues alike appreciate his approachable and compassionate nature, as he takes the time to listen attentively to their concerns, and ensure that they are well-informed and comfortable with their treatment plans. He consistently demonstrates a commitment to individualized care, tailoring approaches to the unique needs of each patient.

Overall, his expertise, passion for research, and patient-centred approach have made him a highly regarded specialist in prostate cancer imaging and therapy, shaping the standard of care in this important area of medicine.

He is very active on social media: he has more than 1600 followers on LinkedIn.